KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Guardant Health (GH) EBITDA (2017 - 2025)

Historic EBITDA for Guardant Health (GH) over the last 9 years, with Q3 2025 value amounting to -$99.0 million.

  • Guardant Health's EBITDA rose 1563.05% to -$99.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$442.4 million, marking a year-over-year increase of 1411.89%. This contributed to the annual value of -$443.6 million for FY2024, which is 2144.96% up from last year.
  • Guardant Health's EBITDA amounted to -$99.0 million in Q3 2025, which was up 1563.05% from -$106.4 million recorded in Q2 2025.
  • Over the past 5 years, Guardant Health's EBITDA peaked at -$97.6 million during Q2 2021, and registered a low of -$197.5 million during Q4 2023.
  • Over the past 5 years, Guardant Health's median EBITDA value was -$113.5 million (recorded in 2023), while the average stood at -$120.0 million.
  • In the last 5 years, Guardant Health's EBITDA plummeted by 20895.68% in 2021 and then surged by 3622.38% in 2024.
  • Over the past 5 years, Guardant Health's EBITDA (Quarter) stood at -$98.2 million in 2021, then plummeted by 48.79% to -$146.1 million in 2022, then tumbled by 35.17% to -$197.5 million in 2023, then surged by 36.22% to -$126.0 million in 2024, then rose by 21.42% to -$99.0 million in 2025.
  • Its EBITDA stands at -$99.0 million for Q3 2025, versus -$106.4 million for Q2 2025 and -$111.0 million for Q1 2025.